Productivity Losses in Pharmacoeconomic Guidelines in Europe and Asia: A Qualitative Review of Guidelines
Author(s)
Nagano M1, Yuasa A2, Yonemoto N3, Ikeda S4
1Pfizer Japan Inc., Koto-ku, 13, Japan, 2Pfizer Japan Inc., Setagaya-ku, 13, Japan, 3Pfizer Japan Inc., Tokyo, Japan, 4International University of Health and Welfare, Narita, Japan
Presentation Documents
OBJECTIVES: Health technology assessment (HTA), including cost-effectiveness analysis (CEA), contributes to the development of equitable, efficient, and high-quality health care systems. The costs considered in CEA may vary depending on the particular health care systems in countries and regions (hereinafter collectively referred to as “countries”). This study aimed to summarize the differences in perspectives and consideration of productivity losses in each country.
METHODS: We conducted a qualitative review of the guidelines relevant to CEA in European and Asian countries and classified the recommended perspectives of guidelines into the payer’s perspective [A], societal perspective [B], specific perspective other than the payer’s or the societal perspectives [C], and multiple perspective [D] categories. In addition, we analyzed the descriptions of productivity losses for patients and caregivers as well as absenteeism and presenteeism.
RESULTS: A total of 33 countries were surveyed, including 25 European and 8 Asian countries. In these countries, 19 (57.6%; 19/33), 8 (24.2%; 8/33), 2 (6.1%; 2/33), and 4 (12.1%; 4/33) guidelines recommended categories A, B, C, and D, respectively, when performing a base case analysis. Of guidelines excluding category A, all (100.0%; 14/14) mentioned patients’ productivity losses, of which 9 (64.3%; 9/14) also addressed caregivers’ productivity losses. Absenteeism and presenteeism were clearly stated in 6 guidelines (42.9%; 6/14), whereas only absenteeism was included in 5 guidelines (35.7%; 5/14). The remaining 3 guidelines (21.4%; 3/14) did not mention the inclusion of absenteeism and presenteeism.
CONCLUSIONS: The recommended perspectives and consideration of productivity loss as reflected in guidelines vary widely across the examined countries. Descriptions regarding productivity loss in the guidelines and background information on health care systems in each country should be comprehensively considered to understand the results of CEA.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
HTA173
Topic
Economic Evaluation, Health Technology Assessment, Study Approaches
Topic Subcategory
Literature Review & Synthesis, Value Frameworks & Dossier Format, Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas